Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Molecular Diagnostics to Launch Service in US in August

NEW YORK, June 26 (GenomeWeb News) - CombiMatrix Molecular Diagnostics today said it plans to launch its first molecular diagnostic service in the USin August.

 

The service uses CMDX's Constitutional Genetic Array Test, which can genetically identify more than 50 "common" genetic disorders, including developmental disorders. The service is already sold in Europethrough Paris-based Array Genomics.

 

CMDX said it's in the "final phases" of internal human and clinical validation.

 

In March, CMDX and Array Genomics said they plan to co-develop and co-market a series of comparative genomic hybridization microarrays for diagnosing genetic anomalies associated with mental retardation, a developmental disorder.

 

Matt Watson, CEO of CMDX, said the subsidiary is "actively developing further tests based on both our oligo- and BAC capabilities that augment our microarray portfolio and over the next three quarters, we have plans to launch three to five additional products into the molecular diagnostics market."

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.